

## SUPPLEMENTARY INFORMATION

### Further Delineation of the KAT6B Molecular and Phenotypic Spectrum.

Tamsin Gannon <sup>1</sup>, Rahat Perveen <sup>1</sup>, H elene Schlecht <sup>1</sup>, Simon Ramsden <sup>1</sup>, Beverley Anderson <sup>1</sup>, Bronwyn Kerr <sup>1</sup>, Ruth Day <sup>1</sup>, Siddharth Banka <sup>1</sup>, Mohnish Suri <sup>2</sup>, Siren Berland <sup>3</sup>, Michael Gabbett <sup>4</sup>, Alan Ma <sup>5</sup>, Stan Lyonnet <sup>6</sup>, Valerie Cormier-Daire <sup>6</sup>, R ustem Yilmaz <sup>7</sup>, Guntram Borck <sup>7</sup>, Dagmar Wiczorek <sup>8</sup>, Britt-Marie Anderlid <sup>9</sup>, Sarah Smithson <sup>10</sup>, Julie Vogt <sup>11</sup>, Heather Moore-Barton <sup>5</sup>, Pelin Ozlem Simsek-Kiper <sup>12</sup>, Isabelle Maystadt <sup>13</sup>, Anne Destr ee <sup>13</sup>, Jessica Bucher <sup>14</sup>, Brad Angle <sup>14</sup>, Shehla Mohammed <sup>15</sup>, Emma Wakeling <sup>16</sup>, Sue Price <sup>17</sup>, Amihood Singer <sup>18</sup>, Yves Sznajer <sup>19</sup>, Annick Toutain <sup>20</sup>, Damien Haye <sup>20</sup>, Ruth Newbury-Ecob <sup>10</sup>, Melanie Fradin <sup>21</sup>, Julie McGaughran <sup>4</sup>, Beyhan Tuysuz <sup>22</sup>, Mark Tein <sup>23</sup>, Katelijne Bouman <sup>24</sup>, Tabib Dabir <sup>25</sup>, Jenneke Van den Ende <sup>26</sup>, Ho Ming Luk <sup>27</sup>, Daniela T Pilz <sup>28</sup>, Jacqueline Eason <sup>2</sup>, Sally Davies <sup>28</sup>, Willie Reardon <sup>29</sup>, Livia Garavelli <sup>30</sup>, Orsetta Zuffardi <sup>31</sup>, Koen Devriendt <sup>32</sup>, Ruth Armstrong <sup>33</sup>, Diana Johnson <sup>34</sup>, Martine Doco-Fenzy <sup>35</sup>, Emilia Bijlsma <sup>36</sup>, Sheila Unger <sup>37</sup>, Hermine E Veenstra-Knol <sup>24</sup>, J urgen Kohlhase <sup>3</sup>, Ivan FM Lo <sup>27</sup>, Janine Smith <sup>5</sup>, DDD study, Jill Clayton-Smith <sup>1</sup>.

<sup>1</sup> Manchester Centre For Genomic Medicine, University of Manchester, St Mary's Hospital, Manchester

Academic Health Science Centre, Manchester M13 9WL

<sup>2</sup> Department of Clinical Genetics, City Hospital, Nottingham

<sup>3</sup> Centre for Medical Genetics and Molecular Medicine, Haukeland University Hospital,

Bergen, Norway

<sup>4</sup> Genetic Health Queensland and University of Queensland. Royal Brisbane and Women's

Hospital, PO Box Herston QLD, 4029 Australia

5 Department of Clinical Genetics, Children's Hospital at Westmead, Sydney, Australia

6 Département de Génétique, Université Paris Descartes-Sorbonne Paris Cité, INSERM

UMR 1163, *Imagine* Institute, Hôpital Necker Enfants Malades, AP-HP, 24, boulevard de  
Montparnasse, 75015 Paris

7 Institute of Human Genetics, University of Ulm, 89081 Ulm Germany

8 Institut für Humangenetik, Universitätsklinikum Essen, Hufelandstr. 55, 45122 Essen,  
Germany

9 Institute of Molecular Medicine and Surgery, Centre for Molecular Medicine, Karolinska  
Institut and Clinical Genetic Department, Karolinska University Hospital, Stockholm,  
Sweden

10 Clinical Genetics, University Hospitals, Bristol, Southwell St, Bristol BS2 8EG

11 Clinical Genetics, Birmingham Women's Hospital NHS Foundation Trust, Birmingham  
B15 2TG

12 Clinical Genetics, Hacettepe University, Ihsan Dogramaci Children's Hospital, 06100,  
Sihhiye, Ankara, Turkey

13 Centre de Génétique Humaine, Institut de Pathologie et de Génétique, Avenue George

Lemaître 25, B-6041 Gosselies, Belgium

14 Division of Genetics, Birth Defects and Metabolism, Children's Hospital of Chicago,

Chicago, Illinois 60611-2991 USA

15 Clinical Genetics, Guys Hospital, Great Maze Pond, London SE1 9RT

16 North West Thames Regional Genetics Service, North West London Hospitals NHS Trust,

Harrow, HA1 3UJ

17 Clinical Genetics, Northampton General Hospital, Cliftonville, Northampton NN1 5BD

18 Paediatrics and Medical Genetics, Barzilai Medical Centre, Ashkelon, Israel

19 Center for Human Genetics, Clinique Universitaire St-Luc, Université Catholique de Louvain, B1200 Brussels, Belgium.

20 Service de Génétique, Centre Hospitalier Universitaire, Tours, France

21 Service de Génétique Médicale CHU Rennes, Université de Rennes, 35203Rennes, France

22 Department of Pediatric Genetics, Cerrahpaşa Medical School, Istanbul University,

Istanbul, Turkey

23. Clinical Genetics, Birmingham Women's Hospital, Birmingham B15 2TG

24 Department of Genetics, University of Groningen, University Medical Centre, Groningen,

The Netherlands

25 Medical Genetics, Belfast City Hospital, Lisburn Rd, Belfast , BT9 7AB

26 Centre For Medical Genetics, Prins Boudewijnlaan 43, 2650 EDEGEM, Belgium

27 Clinical Genetic Service, Department of Health, Hong Kong SAR

28 Institute of Medical Genetics, University Hospital of Wales, Cardiff CF14 4XW

29 National Centre For Medical Genetics, Our Lady's Hospital For Sick Children, Dublin

30 Clinical Genetics Unit, Obstetric and Pediatric Department, Arcispedale S. Maria Nuova,

Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy

31 Institute of Human Genetics, University of Pavia, Pavia, Italy

32 UZ Leuven, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium

33 East Anglian Medical Genetics Service, Addenbrookes Hospital, Cambridge CB2 0QQ

34 Department of Clinical Genetics, Sheffield Children's Hospital, Sheffield S10 2TH

35 Service de Génétique, HMB-CHU Reims 51092 Reims Cedex

36 Leiden University Medical Centre, 2300 RC Leiden, The Netherlands

37 Service de Génétique Médicale, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne,

Switzerland

38 Centre For Human Genetics, Freiburg, Germany

### Molecular analysis

Primers were designed using the software design program, Primer3 (version.0.4.0)

(<http://frodo.wi.mit.edu/primer3/>) and synthesized externally (Invitrogen, Life

Technologies).

### Supplementary Table 1 Primers used for molecular analysis of *KAT6B*

Exon	F name	F Seq 5' 3' direction	R name	R Seq 5' 3' direction	Product size (bp)	Annealing Temp (°C)
3_1	MYST4exon3_1_Fwd	TGCTTAATACAGTCTGGAATACTCTG	MYST4exon3_1_Rev	TCGGCTCCTCAAGTCCTTC	493	57.5
3_2	MYST4exon3_2_Fwd	TTTCCTAAGTCAGCCAAGGG	MYST4exon3_2_Rev	CCACATAAAACTTAAGTGAAACCG	437	57.5
4	MYST4exon4_Fwd	CGTTATTTAGCAGTTTTTCTTTGTT	MYST4exon4_Rev	TGCTATTACGATATAACTGCCTTAAA	350	56
5 to 6	MYST4exon5to6_Fwd	CATTGGCTAGCCTCATCAGC	MYST4exon5to6_Rev	GAACCTGTATACCTCTGAGCTGTC	634	57.5
7	MYST4exon7_Fwd	TTGAGCAGCTTATTACAGCTACAAC	MYST4exon7_Rev	GGAATCTGAGAGAATAACAATCACC	301	57.5
8_1	MYST4exon8_1_Fwd	GAGAAACATCTAGGTGGTGGC	MYST4exon8_1_Rev	GGCAGACTGCACTGGCTGG	668	57.5
8_2	MYST4exon8_2_Fwd	CCACACAAAAGCTAAAACCTCC	MYST4exon8_2_Rev	ACCTATGTGACAAAATAGGAATTGA	638	57.5
9	MYST4exon9_Fwd	TCCCTATTTGCCAGTATGC	MYST4exon9_Rev	TCACAAAAGGATGTTGAAAAGGG	337	57.5
10	MYST4exon10_Fwd	TTGATAGTCACTGGTGAAAGAACC	MYST4exon10_Rev	TCCCTAATTCCTGCTTTAGAATC	283	57.5
11	MYST4exon11_Fwd	AAATTGAACAATATTTAATCTTCCCC	MYST4exon11_Rev	TTTGTACCTTCTAAACACAAAATCAGC	309	57.5
12	MYST4exon12_Fwd	GTTTAGGATTTGAAAATAAAATGAT	MYST4exon12_Rev	AGCCCTGTTCAAAGAATTGG	351	57.5
13	MYST4exon13_Fwd	TACAAGGACAGTGGCAGGTG	MYST4exon13_Rev	CTCAATTTCTAGAGTACAATCACTG	378	57.5
14	MYST4exon14_Fwd	GCGAATGCACCTTCTCTGTTG	MYST4exon14_Rev	TGAATGCACCTATCTCCAGG	433	57.5
15	MYST4exon15_Fwd	CATTAGTGCTAGCATATGTCCG	MYST4exon15_Rev	GACAACGATCTTAATGACTTTCTTAGC	330	57.5
16	MYST4exon16_Fwd	GAGACACTTTGCCATTGATCC	MYST4exon16_Rev	AATAGACAGAATGTCTGCAATGAC	509	57.5
17	MYST4exon17_Fwd	CATGTCTACTGCATATCGACTCAAC	MYST4exon17_Rev	CAGAGGCCTGCTCTTTGG	442	57.5
18_1	MYST4exon18_1_Fwd	GGAATGAATTCAAGTTGCCC	MYST4exon18_1_Rev	GTGATCATCCAAACGTGCAG	637	57.5
18_2	MYST4exon18_2_Fwd	GATGATCTCATCAAACCTGAGG	MYST4exon18_2_Rev	TCTGCACGGGTGTAGTTCTG	694	57.5

18_3	MYST4exon18_3_Fwd	CCGTTTCAGTCTTTGACCCAG	MYST4exon18_3_Rev	AGCCTTGAGGAGACTTGACG	630	57.5
18_4	MYST4exon18_4_Fwd	CCTCCAGCAGTCTGACACAG	MYST4exon18_4_Rev	GCTGGCAATCTGGGTTTG	629	57.5
18_5	MYST4exon18_5_Fwd	CTCCAATGAATCTGCCGC	MYST4exon18_5_Rev	AATTGCTGGTTTGAAATCG	656	57.5

**Supplementary Table 2a Clinical Features of *KAT6B* positive patients**

Individual	Sex	Birth weight (kg)	Typical face	Intellectual Disability/Dev delay	Feeding difficulties	Contractures	Long great toes	Long thumbs	Dental anomalies	Congenital heart defects	Genital anomalies	Thyroid abnormalities	Abnormal patella	Head circumference	Hypotonia	Cleft palate	Corpus callosum	Renal anomalies	Optic atrophy	Other
1	F	3.55	+	++	+	+	+	-	-	-	-	-	-	33	+	-	-	-	NK	
2	F	3.38	+	++	+	+	+	+	+	+	-	-	-	<3	+	-	-	NK	+	
3	F	2.67	+	++	+	+	-	-	+	+	-	-	-	NK	+	-	NK	NK	NK	
4	F	2.70	+	++	+	+	-	-	-	+	-	-	-	NK	+	-	NK	NK	NK	
5	M	3.56	+	+	+	+	+	+	-	-	+	-	-	5-10	+	+/-	+	-	-	Narrow EAM and lacrimal ducts, bifid uvula
6	M	2.92	+	++	NK	+	+	+	+	-	+	+	+	+	+	-	+	NK	NK	
7	M	3.05	+	++	+	+	+	+	+	+	+	+	+	25	+	-	-	-	-	
8	F	2.72	+	++	+	+	+	+	-	+	-	+	+	?	+	-	NK	NK	NK	
9	M	3.81	+	+	+	+	-	+	-	-	+	-	-	25	+	-	-	NK	-	>5 CAL , nystagmus, loose skin
10	F	2.98	+	++	+	-	+	+	+	-	-	-	-	50	+	+	+	-	-	Died 3 years bronchiolitis
11	F	3.4	+	++	+	-	-	+	+	+	-	+	+	50-98	+	+	-	-	-	Hypoventilation, tracheomalacia, hearing loss, small EAM
12	M	2.8	+	++	+	-	+	+	+	-	+	-	-	?	+	+	NK	NK	NK	
13	M	3.46	+/-	++	++	-	+	+/-	-	-	+	+	-	10	+	-	-	-	-	Laryngeal cleft
14	F	3.18	+	++	+	+	-	+	-	+	-	-	-	<3	+	-	-	-	-	
15	F	3.54	+/-	++	-	+	+	+	-	-	-	-	-	?	+	-	?	?	?	
16	F	2.80	+	++	+	+	+	+	+/-	+	-	+	-	<0.4	+	-	-	-	NK	
17	M	3040	+	++	NK	+	-	-	+	-	+	-	+	25	+	-	NK	+	NK	Now age 36. Hypermobility
18	M	?	+	++	+	-	+/-	+/-	NK	+	+	+	-	NK	+	-	-	+	-	Pachygyria, HL
19	M	2.33	++	+	++	+	+	+	+	+	+	-	+	75	+	-	?	?	?	Born 36w deceased
20	F	1.9	+/-	+	++	+/-	-	-	-	+	-	NK	-	NK	-	-	-	-	NK	Malrotation, SNHL
21	M	2.19	+	++	++	+	+	+	NA	I	+	+	-	2-9	-	-	-	-	-	Thyroid agenesis, ing. hernia
22	F	3.3	+	+	++	-	+	+	-	-	-	-	-	10	+	-	NK	+	-	Horner's

23	M	3.92	+/-	++	+	+/-	+/-	+/-	NK	+	+	-	-	<3	+	+	NK	NK	NK	
24	M	3.44	+	++	++	+	-	+/-	+	+	+	+	NK	25-50	+	+	-	-	-	Sensori-neural hearing loss
25	M	2.40	+	++	+	+/-	+	++	NK	+	+	+	-	25	+	+	-	-	+	Cerebellar abn.
26	F	2.89	+	+	+		+	-	-	-	+	-	<3	+	-	-	-	-	myopia	
48	F	3.10	-	++	+	+	-	+	-	+	-	+	<3	+	+	+	+	NK	malrotation	
49	M	2.58	-	++	+	+	-	+	+	+	+	+	-	+	-	NK	NK	NK		
50	M	NK	+/-	++	+	+	+	+	n/a	+	+	+	+	NK	+	-	+	+	NK	
51	F	n/a	n/a	n/a	n/a	++	+	-	n/a	-	-	n/a	?+	nk	n/a	-	+	+	n/a	Fetus 24/40. knee pterygia
53	M	2.81	+	++	NK	-	NK	NK	NK	+	+	+	-	<3	?	+	NK	+	NK	Pre-auricular pit
54	M	3.80	+	++	+	+	-	-	+	+	+	+	+	<3	+	-	+	NK	NK	
55	M	1.90	+	++	-	+	+	+	+	+	+	-	-	-	-	-	NK	NK	NK	
56	M	3.08	+	++	+	-	+	-	+	+	++	+	-	40	+	-	+	-	+	
58	M	50	+	++	+	NK	+	+	+	-	+	-	-	<3	+	-	NK	NK	NK	
59	F	75	+	++	+	NK	+	+	+	-	-	-	+	NK	+	-				Hypoplastic Lacrimal duct
60	F	24	+	++	+	NK	-	-	+	-	-	+	-	-	+	-				
61	M	0.4	+	++	+	NK	+	+	n/k	+	+	+	+	<3	+	+	-	-	NK	hypospadias
62	M	50	+	++	+	NK	+	+	+	+	+	+	-	-	+	-	-	-	+	Athetoid movements
63	F	50	+	++	+	NK	+	+	+	+	-	+	-	-	+	-	NK	-	NK	Mirror movements, absences
64	M	n/k	+	++	+	+	-	-	+	+	+	+	-	NK	+	+	NK	NK	NK	Died at 18m
65	F	9	+	++	+	NK	+	+	+	+	-	+	+	NK	+	+	-	+	NK	
66	F	50	+	++	+	NK	+	+	+	+	-	-	-	-	+	+	-	-	+	Hip dysplasia, seizures
67	F	9	+	++	+	NK	+	+	+	-	-	-	-	-	+	-	-	-	+	11 pairs ribs
68	F	50	+	++	+	NK	+	+	+	-	-	-	-	-	+	+	NK	-	NK	Syncopal episodes
69	M	n/k	+	+	+	NK	-	-	+	-	-	+	-	<3	+	-	-	-	NK	Abn. periventricular s-gnal
71	M	50	+/-	++	+	NK	-	-	-	-	+	-	-	-	+	-	-	-	NK	Mild phenotype

**Supplementary Table 2b Clinical Features of *KAT6B* negative patients**

Individual	Sex	Weight (%)	Typical face	Intellectual Disability/Developmental delay	Feeding difficulties	Contractures	Long great toes	Long thumbs	Dental anomalies	Congenital heart defects	Genital anomalies	Thyroid abnormalities	Abnormal patella	Microcephaly	Hypotonia	Cleft palate	Agnesis of the corpus callosum	Renal anomalies	Optic atrophy
27	M	2	+/-	+	+	-	-	+	-	+	+	-	+	+	-	-	-	-	-
28	F	NK	+/-	+	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
29	M	NK	-	NK	-	+	-	-	-	+	-	-	-	-	-	+	-	-	-
30	M	NK	+/-	+	+	-	-	-	-	+	-	-	-	+	-	-	-	-	-
31	F	NK	+/-	-	+	+	+	+	+	+	-	-	-	+	-	-	-	-	-
32	F	NK	+/-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
33	F	NK	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-	-	-
34	M	NK	+/-	+	+	+	-	-	-	-	-	-	-	+	-	-	-	-	-
35	F	NK	+/-	+	+	+	+	-	-	+	+	-	-	-	+	-	-	-	-
36	M	NK	+/-	+	+	+	-	-	+	+	+	+	-	NK	+	-	-	-	-
37	M	10	+/-	+	-	+	-	-	+	+	-	-	-	+	-	-	NK	-	NK
43	M	NK	+/-	+	+	-	-	-	NK	NK	-	-	-	NK	+/-	-	-	-	-

44	F	3	+	++	++	-	+/-	-	-	-	-	-	-	-	-	-	-	+	-
45	F	NK	+/-	++	+	-	-	-	-	-	-	-	-	NK	++	-	-	-	-
47	M	50	+/-	+	-	-	-	-	-	-	-	-	-	NK	++	-	-	-	-
48	F	<10	+	++	+	-	-	-	-	+	-	-	-	-	+	-	-	-	-
52	M	50	+/-	+	-	+	-	-	-	+	+	-	-	+	+	+	-	-	-
57	M	15	-	++	++	-	-	-	+	-	-	-	-	-	+	-	+	+	-
72	M	NK	+/-	+	+	NK	-	-	+	-	+	-	-	-	-	-	-	-	-
73	M	25	+/-	+	+	NK	-	-	-	-	NK	-	-	+	+	-	-	-	-
74	F	2	+/-	+	+	NK	-	+	-	-	-	-	-	+	-	-	-	-	-
75	?	2-9	+/-	+	-	NK	+	-	-	+	+	-	-	-	-	-	NK	-	NK
76	?	nk	-	+	+	NK	-	-	+	-	-	-	-	-	+	-	NK	NK	NK

**Supplementary Table 3 Summary of published sequence variants in *KAT6B***

**Changes that are highlighted in **GREY** have been seen in more than one patient**

**Reference sequence used NG\_032048.1, covering *KAT6B* transcript NM\_012330.3**

Phenotype	Exon	Mutation	Type of mutation	Predicted protein change	confirmed to be de novo	Publication	Comment
SBBS	18	c.4405dup	indel	p.(Ser1469Phefs*18)	parents not tested	Clayton-Smith et al.	Case 3 in Clayton-



						2011	Smith et al 1994
SBBS	18	c.5370_5373dup	indel	p.(Ile1792Glnfs*12)	parents not tested	Clayton-Smith et al. 2011	
SBBS	15	c.3018del	indel	p.(Glu1007Argfs*5)	De novo	Clayton-Smith et al. 2011	Patient also has 1q21.1 microdup
SBBS	18	c.4069G>T	nonsense	p.(Glu1357*)	De novo	Clayton-Smith et al. 2011	Figure 3 in Day et al 2008
SBBS	18	c.4205_4206del	indel	p.(Ser1402Cysfs*5)	De novo	Clayton-Smith et al. 2011	
SBBS	18	c.5734A>T	nonsense	p.(Arg1912*)	parents not tested	Clayton-Smith et al. 2011	Case 2 in Clayton-Smith et al 1994
SBBS	18	c.5030del	indel	p.(Thr1677Metfs*38)	parents not tested	Clayton-Smith et al. 2011	
SBBS	18	c.5201_5210dup	indel	p.(Gln1737Hisfs*41)	parents not tested	Clayton-Smith et al. 2011	
SBBS	18	c.5201_5210dup	indel	p.(Gln1737Hisfs*41)	De novo	Clayton-Smith et al. 2011	
SBBS	18	c.4205_4206del	indel	p.(Ser1402Cysfs*5)	parents not tested	Clayton-Smith et al. 2011	Case 4 in Clayton-Smith et al 1994
SBBS	3	c.527dup	indel	p.(Tyr176*)	parents not tested	Clayton-Smith et al. 2011	Milder SBBYSS phenotype
SBBS	18	c.4911_4921del	indel	p.(Val1638Alafs*27)	De novo	Clayton-Smith et al. 2011	
SBBS	18	c.5389C>T	nonsense	p.(Arg1797*)	De novo	Clayton-Smith et al. 2011	
SBBYSS	8	c.1078G>A	missense	p.(Glu360Lys)	parents not tested	Clayton-Smith et al. 2011	non-pathogenic, seen in control
GPS	18	c.3892G>T	nonsense	p.(Gly1298*)	parents not tested	Campeau et al. 2012	Case 1 in Abdul-Rahman et al 2006
GPS	18	c.4360_4368delins	indel	p.(Glu1454Lysfs*8)	De novo	Campeau et al. 2012	Case 2 in Abdul-Rahman et al 2006
GPS	18	c.3802G>T	nonsense	p. (Gly1268*)	De novo	Campeau et al. 2012	Case in Lammer and Abrams 2002
GPS	18	c.3769_3772del	indel	p.(Lys1258Glyfs*13)	De novo	Campeau et	Case in

						al. 2012	Lifchez et al 2002
GPS	18	c.3788_3789del	indel	p.(Lys1263Argfs*7)	De novo	Campeau et al. 2012	
GPS	18	c.3769_3772del	indel	p.(Lys1258Glyfs*13)	De novo	Campeau et al. 2012	
GPS	18	c.3680_3695del	indel	p.(Asp1227Glu fs*11)	De novo	Simpson et al. 2012	Case in Brugha et al 2011
GPS	18	c.3768_3771del	indel	p.(Lys1258Glyfs*13)	De novo	Simpson et al. 2012	
GPS	18	c.3768_3771del	indel	p.(Lys1258Glyfs*13)	De novo	Simpson et al. 2012	
GPS	18	c.3877A>T	nonsense	p.(Lys1293*)	De novo	Simpson et al. 2012	
GPS	18	c.3773dup	indel	p.(Trp1259Valfs*12)	De novo	Simpson et al. 2012	
SBBS	18	c.5064_5071del	indel	p.(Met1690Glu fs*24)	De novo	Szakson et al. 2013	
SBBS	18	c.5389C>T	nonsense	p.(Arg1797*)	De novo	Szakson et al. 2013	Case in Szakson et al 2011
SBBS	18	c.5623_5624dup	indel	p.(Gln1875Hisfs*5)	De novo	Yu et al. 2013	Initially suspected to have BPES
SBBS	17	c.3401_3402del	indel	p. (Gly1134Ala fs*2)	parents not tested	Patient 1 This study	
SBBS	18	c.4911_4921del	indel	p.(Val1638Alafs*27)	De novo	Patient 2 This study	
SBBS	18	c.5424C>A	nonsense	p. (Tyr1808*)	parents not tested	Patient 3 This study	
SBBS	18	c.5624_5625del	indel	p.(Ala1876Leufs*3)	parents not tested	Patient 4 This study	
SBBS	18	c.5442_5445del	indel	p.(Phe1815Alafs*8)	De novo	Patient 5 This study	
SBBS	18	c.5209 C>T	nonsense	p.(Gln1737*)	De novo	Patient 6 This study	
SBBS	18	c.4205_4206del	indel	p.(Ser1402Cysfs*5)	De novo	Patient 7 This study	
SBBS	18	c.5115_5116del	indel	p.(Tyr170611efs*9)	De novo	Patient 8 This study	
SBBS	18	c.5731C>T	nonsense	p.(Gln1911*)	parents not tested	Patient 9 This study	
SBBS	18	c.5302 C>T	nonsense	p. (Gln1768*)	parents not tested	Patient 10 This study	
SBBS	18	c.5389 C>T	nonsense	p.(Arg1797*)	parents not tested	Patient 11 This study	
SBBS	16	c.3147 G>A	missense*	p. Pro1049Pro	De novo	Patient 12 This study	
SBBS	16	c.3147 G>A	missense	p. Pro1049Pro	De novo	Patient 13 This study	
SBBS	16	c.3147 G>A	missense	p. Pro1049Pro	De novo	Patient 14 This study	
SBBS	18	c.4728_4729del	indel	p.(Arg1577Cysfs*21)	De novo	Patient 15 This study	
SBBS	18	c.4312del	indel	p.(Glu1438Lysfs*23)	parents not tested	Patient 16 This study	
SBBS	17	c.3366_3369del	indel	p.(Lys1124Glyfs*5)	De novo	Patient 17	

						This study	
SBBS	18	c.5389 C>T	nonsense	p.(Arg1797*)	parents not tested	Patient 18 This study	
SBBS	18	c.5389 C>T	nonsense	p.(Arg1797*)	parents not tested	Patient 19 This study	
SBBS	16	c.3064 G>T	nonsense	p.(Glu1022*)	parents not tested	Patient 20 This study	
SBBS	18	c.4205_4206del	indel	p.(Ser1402Cysfs*5)	parents not tested	Patient 21 This study	
SBBS	18	c.3040C>T	nonsense	p.(Gln1014*)	De novo	Patient 22 This study	
SBBS	18	c.4114G>T	nonsense	p.(Glu1372*)	De novo	Patient 23 This study	
SBBS	18	c.5131del	indel	p.(Ser1711Profs*4)	parents not tested	Patient 24 This study	
SBBS	18	c.5302C>T	nonsense	p.(Gln1768*)	De novo	Patient 25 This study	
SBBS	18	c.2959T>C	missense	p.(Trp987Arg)	parents not tested	Patient 26 This study	
SBBS	18	c.4320_4321del	indel	p.(Lys1441Glyfs*23)	De novo	Patient 53 This study	
SBBS	18	c.4205_4206del	indel	p.(Ser1402Cysfs*5)	De novo	Patient 54 This study	
SBBS	18	c.4074_4079del	indel	p.(Glu1367_Glu1368)	De novo	Patient 55 This study	
GPS	17	c.3598_3622dup25	indel	p.(Gly1208Glyfs*19)	De novo	Patient 48 This study	
GPS	18	c.3962_3963del	indel	p.(Gln1321Argfs*20)	parents not tested	Patient 49 This study	
GPS	18	c.3769_3772del	nonsense	p.(Lys1258Glyfs*13)	Parents not tested	Patient 50 This study	
GPS	18	c.4110dupA	nonsense	p.(Glu1371Argfs*16)	De novo	Patient 51 This study	
GPS/SBBS	18	c.5302C>T	nonsense	p. (Gln1768*)	De novo	Patient 56 This study	

## Supplementary Figure 1

Whole Body Habitus of Patient 17, demonstrating adult phenotype of SBBS



Supplementary Figure 2

Long, straight thumbs which are proximally placed, long hallux and overlapping of toes which are common features in Say Barber Biesecker syndrome.

